Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vertex Pharmaceuticals
Biotech
Vertex drops asset in acute pain after phase 2 fail
All three dose levels of Nav1.8 inhibitor VX-993 failed to improve pain intensity over a 48-hour period compared to placebo.
Darren Incorvaia
Aug 4, 2025 5:34pm
Vertex diabetes islet cell therapy improves blood sugar levels
Jun 23, 2025 4:21am
Vertex consolidates Rhode Island footprint, cuts 125 jobs
Jun 11, 2025 10:38am
Lilly lands next-gen pain asset in $1B SiteOne acquisition
May 27, 2025 11:30am
Vertex takes $379M hit tied to cancelled islet cell program
May 6, 2025 12:50pm
Vertex discontinues AAV research for gene therapies
May 2, 2025 6:22pm
